Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/8/2022 | $0.60 | Buy | Maxim Group |
4 - Guardion Health Sciences, Inc. (0001642375) (Issuer)
3 - Guardion Health Sciences, Inc. (0001642375) (Issuer)
3 - Guardion Health Sciences, Inc. (0001642375) (Issuer)
HOUSTON, TEXAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has filed a certificate of dissolution with the Secretary of State of the State of Delaware, which became effective upon filing on October 30, 2024 (the "Effective Date"). The filing of the certificate was made pursuant to the terms of the Company's Plan of Liquidation and Dissolution (the "Plan") approved by stockholders at the Company's special meeting of stockholders held on May 31, 2024. As of October 30, 2024, Guardion has closed its stock transfer books, and record holders of shares of the Company's common stock, par value $0.001 per
HOUSTON, TEXAS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that its Board of Directors declared a cash dividend in an amount equal to $5.00 per share of common stock held by its stockholders of record on September 9, 2024 and a payment date of September 23, 2024. Forward-Looking Statements The matters described herein may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions re
Guardion Also Provides an Update to Stockholders of Significant Recent Developments HOUSTON, TEXAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers science-based, clinically supported products designed for consumer ocular health, today announced its financial results for the three months and six months ended June 30, 2024, as described below. The Company also provided an update to stockholders of significant recent developments. Recent Developments: Sale of Viactiv® Brand and Business On May 31, 2024, as previously disclosed publicly, the Company completed the sale of all of t
Company Estimates the Aggregate Potential Liquidating Distributions to Range from approximately $9.00 to $11.00 per Share if Stockholders Vote to Approve the Sale of the Company's Viactiv Business and the Plan of Liquidation and Dissolution
8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
8-K - Guardion Health Sciences, Inc. (0001642375) (Filer)
25 - Guardion Health Sciences, Inc. (0001642375) (Filer)
SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)
SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)
SC 13G/A - Guardion Health Sciences, Inc. (0001642375) (Subject)
Maxim Group initiated coverage of Guardion Health Sciences with a rating of Buy and set a new price target of $0.60
HOUSTON, TEXAS, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has filed a certificate of dissolution with the Secretary of State of the State of Delaware, which became effective upon filing on October 30, 2024 (the "Effective Date"). The filing of the certificate was made pursuant to the terms of the Company's Plan of Liquidation and Dissolution (the "Plan") approved by stockholders at the Company's special meeting of stockholders held on May 31, 2024. As of October 30, 2024, Guardion has closed its stock transfer books, and record holders of shares of the Company's common stock, par value $0.001 per
Plan includes Voluntary Delisting of Common Stock from Nasdaq and Suspension of SEC Reporting Obligations HOUSTON, TEXAS, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has notified the Nasdaq Stock Market ("Nasdaq") of its intent to delist its common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Capital Market. Guardion expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of the Common Stock on or about October 11, 2024 and to suspend trading of its Common Stock on the Nas
HOUSTON, TEXAS, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that its Board of Directors declared a cash dividend in an amount equal to $5.00 per share of common stock held by its stockholders of record on September 9, 2024 and a payment date of September 23, 2024. Forward-Looking Statements The matters described herein may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions re
Plan includes Voluntary Delisting of Common Stock from Nasdaq and Suspension of SEC Reporting Obligations HOUSTON, TEXAS, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company") today announced that it has notified the Nasdaq Stock Market ("Nasdaq") of its intent to delist its common stock, par value $0.001 per share (the "Common Stock"), from the Nasdaq Capital Market. Guardion expects to file a Form 25 (Notification of Removal from Listing) with the Securities and Exchange Commission (the "SEC") and Nasdaq relating to the delisting of the Common Stock on or about October 11, 2024 and to suspend trading of its Common Stock on the Nas
HOUSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (NASDAQ:GHSI) ("Guardion" or the "Company"), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced that Janet ("Jan") Hall has been appointed as the Company's new President and Chief Executive Officer. Ms. Hall is assuming these executive positions from Bret Scholtes, who has served in those positions since January 6, 2021. Mr. Scholtes is resigning effective June 9, 2023, and is also concurrently resigning from the Board of Directors of the Company. Ms.
AgEagle Announces Appointment of Kelly Anderson, CPA to the Board of DirectorsWICHITA, KS / ACCESSWIRE / December 7, 2022 / AgEagle Aerial Systems Inc. (NYSE:UAVS) ("AgEagle" or the "Company"), an industry-leading provider of full stack flight hardware, sensors and software for commercial and government/defense use, today announced the appointment of Kelly Anderson, CPA as a new independent member of AgEagle's Board of Directors, effective today, December 5, 2022. Anderson will also serve as Chairperson of the Audit Committee and as a member of both the Compensation Committee and Nominating and Corporate Governance Committee of the Board, effective December 5, 2022."We are very pleased to we